drugset / Trial / NCT00325806

Ramipril - Hypertension

NCT00325806

Phase 4 Completed 1008 enrolled Sanofi
RandomizedParallel-groupOpen-labelTreatment

Summary

Primary objective: Mean values of systolic and diastolic office blood pressure Secondary objectives: Total mortality, occurrence of cardio- and cerebrovascular events, change of mean blood pressure (ABPM : Ambulatory Blood Pressure Monitoring) during the observation

Timeline

Start
2000-05
Primary completion
2005-08
Completion
2005-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Ramipril Small molecule

Indications